Details for New Drug Application (NDA): 021299
✉ Email this page to a colleague
The generic ingredient in PEXEVA is paroxetine mesylate. There are thirty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
Summary for 021299
Tradename: | PEXEVA |
Applicant: | Sebela Ireland Ltd |
Ingredient: | paroxetine mesylate |
Patents: | 1 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
Approval Date: | Jul 3, 2003 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | May 4, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 20MG BASE | ||||
Approval Date: | Jul 3, 2003 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | May 4, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 30MG BASE | ||||
Approval Date: | Jul 3, 2003 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | May 4, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? |
Expired US Patents for NDA 021299
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-002 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-001 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription